Gayathiri Rajakumar

Gayathiri Rajakumar

Auto-generated profile, based on publicly available information

Gayathiri Rajakumar

Charles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia; Sydney Medical School, Nepean Clinical School, Faculty of Medicine and Health, University of Sydney, Kingswood, NSW 2747, Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
AEAnahid Ehteda
Anahid Ehteda
AKAaminah Khan
Aaminah Khan
GRGayathiri Rajakumar
Gayathiri Rajakumar
AVAnne S. Vanniasinghe
Anne S. Vanniasinghe
AGAnjana Gopalakrishnan
Anjana Gopalakrishnan
DZDavid Ziegler
David Ziegler
Diffuse intrinsic pontine gliomas (DIPG) are an incurable childhood brain cancer for which novel treatments are needed. DIPGs are characterized by a mutation in the H3 histone (H3K27M), resulting in loss of H3K27 methylation and global gene dysregulation. TRX-E-009–1 is a novel anticancer agent with preclinical activity demonstrated against a range of cancers. We examined the antitumor activity of TRX-E-009–1 against DIPG neurosphere cultures and observed tumor-specific activity with IC50s ranging from 20 to 100 nmol/L, whereas no activity was observed against normal human astrocyte cells. TRX-E-009–1 exerted its anti-proliferative effect through the induction of apoptotic pathways, with marked increases in cleaved caspase 3 and cleaved PARP levels, while also restoring histone H3K27me3 methylation. Co-administration of TRX-E-009–1 and the histone deacetylase (HDAC) inhibitor SAHA extended survival in DIPG orthotopic animal models. This antitumor effect was further enhanced with irradiation. Our findings indicate that TRX-E-009–1, combined with HDAC inhibition, represents a novel, potent therapy for children with DIPG.

11 October 2024 in Ageing Research Reviews
Verified
Journal Article
Open access
GRGayathiri Rajakumar
Gayathiri Rajakumar
MCMaria Lastra Cagigas
Maria Lastra Cagigas
TWTian Wang
Tian Wang
APAngela Y. Pan
Angela Y. Pan
TPTiana Pelaia
Tiana Pelaia
LFLuigi Fontana
Luigi Fontana
Insulin-like growth factor (IGF)-1 plays a role in aging and cancer biology, with fasting known to reduce serum IGF-1 levels in human adults. However, the impact of ad libitum ketogenic diets (KDs) on IGF-1 levels remains unclear. Adhering to PRISMA guidelines, we conducted a meta-analysis of human trials by systematically searching Ovid, PubMed, Scopus, and CENTRAL Libraries until June 2023. Eligible studies prescribed KDs to adults of any health status, confirmed ketosis, and measured serum IGF-1. Protocols involving prescribed fasting or energy restriction were excluded. Mean differences (MD) and 95 % confidence intervals (CIs) were calculated longitudinally between pre- and post-intervention measurements for the KD groups. Among twelve publications meeting the inclusion criteria, 522 individuals participated, with 236 completing KDs. The intervention duration ranged from 1 to 20 weeks. Pooled results from ten trials showed a significant reduction in serum IGF-1 levels post-intervention (MD: -24.9 ng/mL [95 % CI -31.7 to -18.1]; p55 % fat) effectively induce ketosis and can lower serum IGF-1 by 20 %, fasting glucose by 6 % and insulin by 29 %. This clinically notable reduction in IGF-1 can be attained without the need for a prescribed fasting or severe calorie restriction regimen. Further investigation is warranted to explore the impact of KDs on ageing biomarkers and cancer management.

1 December 2023
Verified
Other
Open access
AEAnahid Ehteda
Anahid Ehteda
AKAaminah Khan
Aaminah Khan
GRGayathiri Rajakumar
Gayathiri Rajakumar
AVAnne S. Vanniasinghe
Anne S. Vanniasinghe
AGAnjana Gopalakrishnan
Anjana Gopalakrishnan
DZDavid Ziegler
David Ziegler
Diffuse intrinsic pontine gliomas (DIPG) are an incurable childhood brain cancer for which novel treatments are needed. DIPGs are characterized by a mutation in the H3 histone (H3K27M), resulting in loss of H3K27 methylation and global gene dysregulation. TRX-E-009–1 is a novel anticancer agent with preclinical activity demonstrated against a range of cancers. We examined the antitumor activity of TRX-E-009–1 against DIPG neurosphere cultures and observed tumor-specific activity with IC50s ranging from 20 to 100 nmol/L, whereas no activity was observed against normal human astrocyte cells. TRX-E-009–1 exerted its anti-proliferative effect through the induction of apoptotic pathways, with marked increases in cleaved caspase 3 and cleaved PARP levels, while also restoring histone H3K27me3 methylation. Co-administration of TRX-E-009–1 and the histone deacetylase (HDAC) inhibitor SAHA extended survival in DIPG orthotopic animal models. This antitumor effect was further enhanced with irradiation. Our findings indicate that TRX-E-009–1, combined with HDAC inhibition, represents a novel, potent therapy for children with DIPG.

1 December 2023
Verified
Other
Open access
AEAnahid Ehteda
Anahid Ehteda
AKAaminah Khan
Aaminah Khan
GRGayathiri Rajakumar
Gayathiri Rajakumar
AVAnne S. Vanniasinghe
Anne S. Vanniasinghe
AGAnjana Gopalakrishnan
Anjana Gopalakrishnan
DZDavid Ziegler
David Ziegler
Diffuse intrinsic pontine gliomas (DIPG) are an incurable childhood brain cancer for which novel treatments are needed. DIPGs are characterized by a mutation in the H3 histone (H3K27M), resulting in loss of H3K27 methylation and global gene dysregulation. TRX-E-009–1 is a novel anticancer agent with preclinical activity demonstrated against a range of cancers. We examined the antitumor activity of TRX-E-009–1 against DIPG neurosphere cultures and observed tumor-specific activity with IC50s ranging from 20 to 100 nmol/L, whereas no activity was observed against normal human astrocyte cells. TRX-E-009–1 exerted its anti-proliferative effect through the induction of apoptotic pathways, with marked increases in cleaved caspase 3 and cleaved PARP levels, while also restoring histone H3K27me3 methylation. Co-administration of TRX-E-009–1 and the histone deacetylase (HDAC) inhibitor SAHA extended survival in DIPG orthotopic animal models. This antitumor effect was further enhanced with irradiation. Our findings indicate that TRX-E-009–1, combined with HDAC inhibition, represents a novel, potent therapy for children with DIPG.